You are here

  • Home
  • Archive
  • Volume 9, Issue 11
  • Influence of government price regulation and deregulation on the price of antineoplastic medications in China: a controlled interrupted time series study

Article info

Article menu

Download PDFPDF

XML
Health policy
Original research
Influence of government price regulation and deregulation on the price of antineoplastic medications in China: a controlled interrupted time series study

Authors

  • Xiaodong Guan Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing, China Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Haishaerjiang Wushouer Center for Strategic Studies, Chinese Academy of Engineering, Beijing, China School of Medicine, Tsinghua University, Beijing, China PubMed articlesGoogle scholar articles
  • Mingchun Yang Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing, China PubMed articlesGoogle scholar articles
  • Sheng Han International Research Center for Medicinal Administration, Peking University, Beijing, China PubMed articlesGoogle scholar articles
  • Luwen Shi Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing, China PubMed articlesGoogle scholar articles
  • Dennis Ross-Degnan Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Anita Katharina Wagner Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  1. Correspondence to Professor Luwen Shi; shiluwen211{at}163.com
View Full Text

Citation

Guan X, Wushouer H, Yang M, et al
Influence of government price regulation and deregulation on the price of antineoplastic medications in China: a controlled interrupted time series study
BMJ Open 2019;9:e031658. doi: 10.1136/bmjopen-2019-031658

Publication history

  • Received May 14, 2019
  • Revised November 11, 2019
  • Accepted November 11, 2019
  • First published November 28, 2019.
Online issue publication 
October 13, 2022
Previous versions
Review history

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.